Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations

Mutant p53 proteins (mutant p53s) have oncogenic gain-of-function properties correlated with tumor grade, castration resistance, and prostate cancer (PCa) tumor recurrence. Docetaxel is a standard first-line treatment for metastatic castration-resistant PCa (mCRPC) after the failure of hormone thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiangyan, Wu, Jason Boyang, Chung, Leland W.K., Huang, Wen-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747386/
https://www.ncbi.nlm.nih.gov/pubmed/26512780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747386/
https://www.ncbi.nlm.nih.gov/pubmed/26512780

Ejemplares similares